RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Fast Track (United States)

Structure/Sequence

Molecular FormulaC33H42F3N9O2S2

InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N

CAS Registry2134675-36-6

Clinical Trials associated with Ziftomenib

NCT07411586

/ Not yet recruitingPhase 1IIT

Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes.
The goal of Phase 1b is to learn if the recommended dose of ziftomenib and olutasidenib found in Phase 1 can help to control the disease.
The safety and effects of this combination will also be studied in both parts.

Start Date31 Aug 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT07355335

/ Not yet recruitingPhase 1IIT

A Phase 1 Study of Menin-KMT2A Inhibitor Ziftomenib (KO-539) in Combination With Cereblon E3 Ligase Modulator Mezigdomide (CC-92480) in Adolescents and Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).

Start Date09 Jul 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+2]

NCT06930352

/ Not yet recruitingPhase 2IIT

Frontline Ziftomenib in NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction or Other Therapy

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

Start Date10 Apr 2026

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Ziftomenib

100 Translational Medicine associated with Ziftomenib

100 Patents (Medical) associated with Ziftomenib

Literatures (Medical) associated with Ziftomenib

01 Apr 2026·AMERICAN JOURNAL OF HEMATOLOGY

The Care and Cure of the Leukemias in 2026

Review

Author: Wierda, William ; Kantarjian, Hagop ; Kadia, Tapan ; Haddad, Fadi G. ; Freireich, Emil J. ; Ravandi, Farhad ; Chifotides, Helen T. ; Jabbour, Elias ; Jain, Nitin ; Welch, Mary Alma

ABSTRACT:

It is an exciting era in leukemia owing to the development of novel targeted therapies and advances in genomics, pathophysiology, prognostication, and monitoring (e.g., highly sensitive measurable residual disease assays). Currently, most leukemias are effectively treated with immunotherapies (highly effective monoclonal antibodies targeting CD19 [blinatumomab], or CD22 [inotuzumab ozogamicin]), BCR::ABL1 tyrosine kinase inhibitors (TKIs; e.g., dasatinib, ponatinib), Bruton TKIs (e.g., ibrutinib, acalabrutinib), BCL‐2 inhibitors (venetoclax), IDH1/2 inhibitors (ivosidenib, olutasidenib, and enasidenib), FLT3 inhibitors (e.g., midostaurin, quizartinib, and gilteritinib), menin inhibitors (revumenib, ziftomenib), and chimeric antigen receptor T‐cell therapies. These novel agents and their judicious use in combination strategies have transformed the treatment landscape across all leukemias, significantly increased survival and quality of life for patients, and attenuated the need for intensive chemotherapy and hematopoietic stem cell transplantation. Leukemia subtypes, such as Philadelphia‐positive acute lymphoblastic leukemia (incurable before 2000) and chronic lymphocytic leukemia (previously considered incurable) with historically dire prognoses were recently transformed to favorable leukemias with 5‐ and 10‐year survival rates of 80+% and 90+%, respectively. The BCR::ABL1 TKIs resulted in normal life expectancy in chronic myeloid leukemia. Notable advances have also been made in AML with targeted therapies, although some subsets (older/unfit patients for intensive chemotherapy, complex karyotype, TP53 ‐mutated, KMT2A ‐rearranged, and treated secondary AML) still have unfavorable outcomes. Herein, we provide a high‐level overview of prominent clinical developments across all leukemias. In contemporary times, harnessing the benefits of novel targeted therapies and the evolving treatment landscape bolster the optimistic view that most, if not all, leukemias are curable.

01 Mar 2026·CANCER

Two new options for NPM1 ‐mutated relapsed, refractory acute myeloid leukemia

Author: Lawrence, Leah

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA recently approved two menin inhibitors for the treatment of relapsed or refractory acute myeloid leukemia with NPM1 mutations: revumenib and ziftomenib. In addition, the FDA also approved the subcutaneous injection of anti‐CD38 monoclonal antibody daratumumab and hyaluronidase‐fihj for patients with high‐risk smoldering multiple myeloma, and oral TKI sevabertinib is approved for advanced HER2 ‐mutant NSCLC.

05 Dec 2025·Hematology-American Society of Hematology Education Program

The promise of menin inhibitors: from approval to triplet regimens

Review

Author: Thakur, Rahul K. ; Wang, Eunice S.

Abstract:

Pharmacologic targeting of the menin-KMT2A protein–protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved accelerated regulatory approval in November 2024 for monotherapy of relapsed/refractory KMT2A rearranged leukemia. Next-generation agents (ziftomenib, bleximenib, enzomenib, BMF-219) have displayed similar composite complete remission rates (20-35%) and overall response rates (45-65%) in heavily pretreated KMT2Ar and NPM1m acute myeloid leukemia (AML) with measurable residual disease (MRD) negativity and prolonged overall survival (5–7 months). While all menin inhibitors result in on-target blast differentiation with clinical sequelae (“differentiation syndrome”) in 10% to 20% of patients, not all menin inhibitors are the same, with differing safety, toxicity (heartrate corrected QT interval (QTc) prolongation, cytopenias), and pharmacokinetic profiles. Acquired mutations in the menin gene described in 39% of post-revumenib relapses have not been identified following other inhibitors (ziftomenib, bleximenib), prompting new questions about resistance mechanisms. These promising results swiftly led to the launch of multiple trials of menin inhibitors combined with intensive (cytarabine and anthracycline) and nonintensive (venetoclax and hypomethylating) chemotherapy backbones. To date, these triplets have yielded high response rates (ie, ≥80% in de novo, 50-70% in relapsed) with most patients achieving MRD negativity and prolonged one-year survival. Ongoing/pending phase 3 trials will clarify whether menin blockade should be incorporated into frontline and maintenance regimens for all patients with KMT2A rearranged or NPM1 mutant disease. In the current era, menin inhibition remains a key pillar of the success of precision medicine for AML therapy.

180

News (Medical) associated with Ziftomenib

25 Apr 2026

·www.biospace.com

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

– Regulatory Filing in Japan Planned Following Clinical Trial Completion – April 24, 2026 -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been dosed in a Japanese Phase 2 registrational clinical trial (jRCT2031250550) studying ziftomenib, an oral menin inhibitor, for the treatment of relapsed or refractory (R/R) NPM1-mutated (NPM1-m) acute myeloid leukemia (AML). NPM1-m AML accounts for approximately 30% of AML patients. The initiation of this trial represents a significant step forward toward establishing a potential new treatment option for patients in Japan. Following completion of this clinical trial, Kyowa Kirin plans to file for regulatory approval in Japan. Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1-m AML who have no satisfactory alternative treatment options, under the brand name KOMZIFTI™. “Patients with R/R NPM1-m AML often face limitations with existing treatment options and have a critical need for new therapeutic alternatives. Ziftomenib has the potential to provide a new treatment approach for these patients,” said Yoshifumi Torii, Ph.D., Chief Medical Officer of Kyowa Kirin. “The initiation of this trial is part of Kyowa Kirin's patient-centered drug development efforts in our priority area of 'hematologic malignancies and refractory hematologic disorders.' We will appropriately advance this trial and work diligently to confirm efficacy and safety, with the goal of ultimately providing a new treatment option to help address unmet needs for patients in Japan as soon as possible.” The trial initiated by Kyowa Kirin is a multicenter, single-arm, open-label Japanese Phase 2 clinical trial evaluating the efficacy and safety of ziftomenib in adult patients with R/R NPM1-m AML. As the primary endpoint, the trial will assess a composite complete remission rate consisting of complete remission (CR) and complete remission with partial hematologic recovery (CRh). “The initiation of the Phase 2 clinical trial of ziftomenib in Japan represents a significant milestone in our global development strategy,” said Mollie Leoni, M.D., Chief Medical Officer at Kura Oncology. “In R/R NPM1-m AML, therapeutic options remain limited in many regions and patient populations, highlighting the urgent need for innovative therapies. In clinical trials outside of Japan, ziftomenib has consistently shown a favorable efficacy and safety profile combined with the convenience of once-daily oral administration. Advancing clinical development in Japan is a meaningful step toward establishing global access to this promising therapy. We look forward to close collaboration with Kyowa Kirin to support the trial and deliver new hope to patients in need.” Kyowa Kirin Co., Ltd. is committed to the research and development of innovative medicines in areas of high unmet medical need. Ziftomenib is in development in combination with standard-of-care and targeted therapies for the front-line treatment of AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to benefit a broad spectrum of patients earlier in their disease course. NPM1, nucleophosmin 1, KMT2A, lysine methyltransferase 2A, FLT3, Fms-like tyrosine kinase 3 U.S. KOMZIFTI™ (ziftomenib) Indication KOMZIFTI is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. The content above comes from the network. if any infringement, please contact us to modify.

18 Apr 2026

·www.biospace.com

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off April 17, 2026 -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib in the ongoing FIT-001 clinical trial (NCT06026410) of darlifarnib (KO-2806) in combination with cabozantinib. Results were presented at the 2026 International Kidney Cancer Symposium (IKCS): Europe in Paris, France. The analysis specifically evaluated patients with ccRCC who had previously received cabozantinib, a population that typically derives limited benefit from subsequent therapy. In this setting, the combination of darlifarnib and cabozantinib demonstrated robust antitumor activity along with a manageable safety pro demonstrated in all RCC patients across multiple dose levels, including full dose cabozantinib. These findings are consistent with clinical and preclinical data presented at the 2025 European Society for Medical Oncology (ESMO) and in earlier data disclosures supporting the potential of darlifarnib to enhance the activity of VEGFR-targeted therapies and to address mechanisms of resistance. Objective response rate (ORR) was 44%, with a disease control rate (DCR) of 94% across all doses tested in this population Tumor shrinkage observed in 75% of patients, with reductions ranging from 32% to 47% among responders Antitumor activity observed in a heavily pre-treated, cabozantinib-exposed population, including patients whose best response to prior cabozantinib was stable disease Responses observed in patients previously treated with cabozantinib in the immediate prior line as well as those who had received other TKIs in addition to cabozantinib Treatment durations ranged from 8 to 56 weeks, with six patients remaining on therapy at the time of data cutoff These findings are notable given that patients who progress on cabozantinib are generally considered unlikely to respond to subsequent cabozantinib therapy. “Patients with advanced ccRCC whose disease progresses on cabozantinib have limited treatment options,” said Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. “The tumor shrinkage and high disease control rate observed with darlifarnib in combination with cabozantinib suggest this approach may offer meaningful clinical benefit in a refractory setting or in patients with disease progression after therapy.” The FIT-001 study is evaluating darlifarnib in patients with RCC at once-daily doses of 3 mg, 5 mg or 8 mg alternating 7 days on and off in combination with cabozantinib at once-daily doses of 60 mg or 40 mg. All patients must have received prior immunotherapy. The study has advanced into Phase 1b dose expansion to assess an optimal biologically active dose for the combination. “These data highlight the potential of darlifarnib to overcome resistance to prior cabozantinib and enhance the activity of VEGF TKIs in patients with advanced RCC,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “We are highly encouraged by these results and are committed to advancing this combination to evaluate further its potential to deliver meaningful benefit for RCC patients.” 2026 IKCS: Europe Presentation The presentation from 2026 IKCS: Europe is available on Kura’s website at under the Posters and Presentations tab in the Farnesyl Transferase Inhibition section. Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultImmunotherapyDrug Approval

09 Apr 2026

·www.biospace.com

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial ( NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France. The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) Congress, where the combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety pro patients with advanced renal cell carcinoma. IKCS Europe 2026 Presentation Details Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001 Abstract Session: 7 Date: April 17, 2026 Time: 3:30 p.m. – 4:30 p.m. CEST Virtual Investor Event Kura will host a webcast and conference call on April 17, 2026, at 7:30 am PT / 10:30 am ET / 4:30 pm CEST featuring management and a clinical investigator from the darlifarnib program. The live webcast and replay will be available on the Company’s website at under the Investors tab in the Events and Presentations section. About darlifarnib Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling. This mechanism has potential to enhance the activity of multiple targeted therapies, including VEGFR-targeted therapies such as cabozantinib. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at and follow us on X and LinkedIn . Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding Kura’s presentation of FIT-001 data at IKCS Europe 2026, the therapeutic potential of the combination of darlifarnib and cabozantinib in patients with clear cell renal cell carcinoma, and the potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy and to enhance the activity of multiple targeted therapies. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact Investors and Media: Greg Mann 858-987-4046 gmann@kuraoncology.com

Phase 1Clinical Result

100 Deals associated with Ziftomenib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute myeloid leukemia with mutated NPM1	United States	Kura Ltd.Sti.	13 Nov 2025
Acute myeloid leukemia with mutated NPM1	United States	Kura Oncology, Inc.	13 Nov 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	France	Kura Oncology, Inc.	26 Sep 2025
Acute Myeloid Leukemia	Phase 3	South Korea	Kura Oncology, Inc.	26 Sep 2025
Acute myeloid leukaemia with 11q23 abnormality	Phase 2	United States	Kura Oncology, Inc.	10 Apr 2026
Acute Lymphoblastic Leukemia	Phase 2	United States	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Belgium	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Canada	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	France	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Germany	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Italy	Kura Oncology, Inc.	12 Sep 2019
Acute Lymphoblastic Leukemia	Phase 2	Poland	Kura Oncology, Inc.	12 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05735184 (KOMET-007, ASH2025)	Phase 1	Acute myeloid leukemia with mutated NPM1 NPM1-mutation	39	AzacitidineVenetoclax 600 mg + AzacitidineVenetoclax + AzacitidineVenetoclaxe (Newly diagnosed NPM1-m AML)	jfmnodtkjm(bfbjqbkxup) = bxypzlltyd hnksvjzqxk (galmhjaeor ) View more	Positive	06 Dec 2025
NCT04067336 (KOMET-001, Pubmed \| J Clin Oncol)	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1-mutated	92	Ziftomenib 600 mg	avfpiledoz(nvhujsqxgu) = hwonqobqiu noagrsecwc (zqfbbgqqnq, 14 - 32) View more	Positive	01 Nov 2025
NCT04067336 (KOMET-001, ASCO2025) Manual	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 1b/2)	pimdxmnrsw(eclqnwpjpn) = hwyfrtppwo jmtdvcdspo (vkfeuxwwau, 17 - 34) View more	Positive	30 May 2025
NCT04067336 (KOMET-001, ASCO2025) Manual	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1 Mutation	112	Ziftomenib 600 mg QDZiftomenib 600 mg QD (Phase 2)	pimdxmnrsw(eclqnwpjpn) = svygfqodab jmtdvcdspo (vkfeuxwwau, 15 - 33)	Positive	30 May 2025
NCT04067336 (KOMET-001, EHA2025)	Phase 1/2	Acute myeloid leukemia with mutated NPM1 NPM1-mutant	112	Ziftomenib 600 mg QD	qnhgzavstn(zadlndgnbm) = qqcdewnhbv gbnrhcmtjv (azzqijtqnj, 17 - 34) View more	Positive	22 May 2025
NCT05735184 (KOMET-007, EHA2025)	Phase 1	Acute myeloid leukaemia with 11q23 abnormality \| Acute myeloid leukemia with mutated NPM1 NPM1-m \| KMT2A-r	51	Ziftomenib 600 mg QD + 7+3 induction	gnblbmnkwb(nnwfnqcqur) = febrile neutropenia (47%), decreased platelet count (31%), anemia (22%), decreased neutrophil count (20%), decreased white blood cell count (16%) qcdfetcqez (gukplccwxm ) View more	Positive	14 May 2025
NCT04067336 (KOMET-001, Company_Website) Manual	Phase 1/2	Acute Myeloid Leukemia NPM1 Mutation	-	Ziftomenib	bnegqxorzr(mqprnugrqj) = The KOMET-001 trial achieved its primary endpoint of CR plus CR with partial hematological recovery (CRh) and the primary endpoint was statistically significant. msysbpjxay (xiqjrhfbyi ) Met View more	Positive	07 Feb 2025
KOMET-007 (GlobeNewswire) Manual	Phase 1	Acute myeloid leukemia with mutated NPM1 \| Acute Leukemia with a KMT2A Translocation First line NPM1 Mutation \| KMT2A Rearrangement	54	ziftomenib +venetoclax/azacitidine	tabjkhwmyj(vfhjhpgvep) = ylovzpqjpn synorbunua (dowiytisoy ) View more	Positive	09 Dec 2024
KOMET-007 (GlobeNewswire) Manual	Phase 1		54	Ziftomenib+cytarabinecytarabine/daunorubicindaunorubicin	tabjkhwmyj(vfhjhpgvep) = xopdbjpclr synorbunua (dowiytisoy ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	-	-	Ziftomenib 200 mg	xxaqlzwvwf(daeodbcvso) = vkgyyxudli icqyjlzjho (yetgicucse ) View more	-	08 Dec 2024
ASH2024	Not Applicable	-	-	Ziftomenib 400 mg	xxaqlzwvwf(daeodbcvso) = eweaylnptp icqyjlzjho (yetgicucse ) View more	-	08 Dec 2024
ASH2024	Not Applicable	-	-	Ziftomenib 200 mg	rwrvznwngq(hdjpmiqqkv) = xkpteyxpgl ppwojptlnx (phfhyshrlu )	-	07 Dec 2024
ASH2024	Not Applicable	-	-	Ziftomenib 400 mg	rwrvznwngq(hdjpmiqqkv) = nneslwopro ppwojptlnx (phfhyshrlu )	-	07 Dec 2024
NCT04067336 (KOMET-001, Pubmed \| Lancet Oncol) Manual	Phase 1/2	Acute Myeloid Leukemia NPM1 Mutation \| KMT2A Rearrangement	83	Ziftomenib 50-1000 mg	yjfyprarmt(myodmansou) = the most common grade 3 or worse treatment-emergent adverse events were anaemia (20 [24%]), febrile neutropenia (18 [22%]), pneumonia (16 [19%]), differentiation syndrome (12 [15%]), thrombocytopenia (11 [13%]), and sepsis (ten [12%]). uqwqotrayw (rnmrqsutae ) View more	Positive	01 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ziftomenib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation